TCR β chain–directed bispecific antibodies for the treatment of T cell cancers

T细胞 抗原 抗体 嵌合抗原受体 T细胞受体 免疫学 免疫疗法 癌症研究 细胞毒性T细胞 癌症 生物 医学 免疫系统 体外 内科学 生物化学
作者
Suman Paul,Alexander H. Pearlman,Jacqueline Douglass,Brian J. Mog,Emily Han-Chung Hsiue,Michael S. Hwang,Sarah R. DiNapoli,Maximilian F. Konig,Patrick Andrew Brown,Katharine M. Wright,Surojit Sur,Sandra B. Gabelli,Yana Li,Gabriel Ghiaur,Drew M. Pardoll,Nickolas Papadopoulos,Chetan Bettegowda,Kenneth W. Kinzler,Shibin Zhou,Bert Vogelstein
出处
期刊:Science Translational Medicine [American Association for the Advancement of Science]
卷期号:13 (584) 被引量:61
标识
DOI:10.1126/scitranslmed.abd3595
摘要

Immunotherapies such as chimeric antigen receptor (CAR) T cells and bispecific antibodies redirect healthy T cells to kill cancer cells expressing the target antigen. The pan-B cell antigen-targeting immunotherapies have been remarkably successful in treating B cell malignancies. Such therapies also result in the near-complete loss of healthy B cells, but this depletion is well tolerated by patients. Although analogous targeting of pan-T cell markers could, in theory, help control T cell cancers, the concomitant healthy T cell depletion would result in severe and unacceptable immunosuppression. Thus, therapies directed against T cell cancers require more selective targeting. Here, we describe an approach to target T cell cancers through T cell receptor (TCR) antigens. Each T cell, normal or malignant, expresses a unique TCR β chain generated from 1 of 30 TCR β chain variable gene families (TRBV1 to TRBV30). We hypothesized that bispecific antibodies targeting a single TRBV family member expressed in malignant T cells could promote killing of these cancer cells, while preserving healthy T cells that express any of the other 29 possible TRBV family members. We addressed this hypothesis by demonstrating that bispecific antibodies targeting TRBV5-5 (α-V5) or TRBV12 (α-V12) specifically lyse relevant malignant T cell lines and patient-derived T cell leukemias in vitro. Treatment with these antibodies also resulted in major tumor regressions in mouse models of human T cell cancers. This approach provides an off-the-shelf, T cell cancer selective targeting approach that preserves enough healthy T cells to maintain cellular immunity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
清茶颂歌完成签到,获得积分10
刚刚
刚刚
何英完成签到,获得积分20
1秒前
苍蓝星完成签到,获得积分10
1秒前
2秒前
桐桐的应助被小红采纳,获得10
2秒前
只为更出色完成签到,获得积分10
3秒前
胡萝卜卜发布了新的文献求助10
3秒前
3秒前
仇剑封完成签到,获得积分10
3秒前
小蘑菇的应助被abin采纳,获得10
3秒前
脑洞疼的应助被hhh采纳,获得10
4秒前
传奇3的应助被吱吱采纳,获得30
4秒前
Firsterchao完成签到,获得积分0
4秒前
6秒前
6秒前
7秒前
桐桐的应助被任我采纳,获得10
7秒前
上官若男的应助被普兴强采纳,获得10
8秒前
糊涂涂完成签到,获得积分10
8秒前
null的应助被温暖砖头采纳,获得10
9秒前
陈懿完成签到,获得积分10
9秒前
9秒前
YANGTIAN完成签到,获得积分10
10秒前
10秒前
橙C发布了新的文献求助10
10秒前
10秒前
ho完成签到 ,获得积分10
11秒前
十三月的篇章完成签到,获得积分10
11秒前
11秒前
嘟噜嘟噜完成签到,获得积分10
12秒前
Miraitowa完成签到,获得积分10
12秒前
12秒前
12秒前
13秒前
152455发布了新的文献求助10
13秒前
笨笨行云的应助被何英采纳,获得20
15秒前
迷路的笑槐完成签到,获得积分10
15秒前
嘟噜嘟噜发布了新的文献求助10
15秒前
冰可乐完成签到 ,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170973
求助须知:如何正确求助?哪些是违规求助? 9563727
关于积分的说明 21771951
捐赠科研通 7762452
什么是DOI,文献DOI怎么找? 3430786
关于科研通互助平台的介绍 2554629
邀请新用户注册赠送积分活动 2475637